NUTRACEUTICAL PRICING ISSUES
Drug regulator oversight sought for nutraceuticals; NGO flags quality, pricing concerns
A Gujarat NGO is pushing the government to regulate nutraceuticals like medicines. They cite concerns about product quality and unregulated prices. The NGO wants these health supplements to be overseen by drug regulators, not food safety authorities. This move aims to ensure better standards and fair pricing for consumers across India.
War, crude oil spike and sugar stocks: Buy them for the right reason – or don’t. 5 sugar stocks from different regions of the country
India imports roughly 85% of its crude oil. Every dollar increase in Brent oil price hits the import bill, pressures the rupee, and makes the domestic fuel mix expensive. Ethanol, produced from sugarcane, maize, or rice is blended into petrol as a partial substitute. The more expensive petrol becomes, the stronger the economic rationale for maximising that blend. From a modest 1.5% blending rate in 2014, it has effectively reached the 20% E20 target by mid-2025 (five years ahead of the original 2030 deadline). So the macro story is real. Ethanol matters. Blending is happening. The government is committed. However…
AI jitters continue to hit IT; USV Pharma buys Wellbeing stake
IT stocks slid sharply Thursday on rising fears of AI-led disruption. Here’s more in today’s ETtech Top 5:
Accretion Nutraveda IPO heads for listing today. Check GMP ahead of debut
Accretion Nutraveda IPO: Demand from non-institutional investors stood at 2.08 times, while the qualified institutional buyers’ portion was subscribed marginally at 1.01 times. The company had also raised Rs 7.02 crore from anchor investors ahead of the public issue.
Sudeep Pharma shares rally 8% after solid listing pop. Should you buy, sell or hold?
Sudeep Pharma’s strong stock market debut turned into an early rally, with shares gaining up to 8% after listing at a nearly 24% premium to the IPO price. The Rs 895 crore issue drew heavy demand across all investor categories, reflecting confidence in the company’s position in speciality pharma ingredients. While analysts see long-term potential backed by high margins and strong export presence, they advise caution on near-term risks such as margin pressure and raw material volatility, suggesting partial profit booking with a disciplined stop-loss.
Aptus Pharma IPO opens for subscription today. GMP, price band among key things to know
Aptus Pharma is set to launch its IPO on Tuesday. The company aims to raise Rs 13.02 crore through a fresh issue. The IPO price is fixed between Rs 65 and Rs 70 per share. The IPO will be listed on BSE SME platform. The company will use the funds for capital expenditure and working capital requirements.
- Go To Page 1
Gem Aromatics shares surge another 5% after modest listing on NSE, BSE. What should investors do?
Gem Aromatics' shares experienced a surge, reaching a day's high of Rs 349 on the BSE after a debut with a modest premium. The IPO, which was subscribed 30.45 times, saw significant interest from institutional and retail investors. Funds raised will be used to repay borrowings and for general corporate purposes.
Gem Aromatics shares list at 2% premium over IPO price
Gem Aromatics made a muted debut on the stock market, listing with a slight premium on the NSE and flat on the BSE after its Rs 451.25 crore IPO. The IPO, subscribed 30.45 times overall, will use proceeds to repay borrowings and for corporate purposes. The company, a manufacturer of speciality ingredients, reported increased revenue and profit in FY25.
Anlon Healthcare IPO opens for subscription today; GMP at 6%. Should you apply?
Anlon Healthcare launches its Rs 121 crore IPO today. The IPO will remain open until August 29. The company will offer 1.33 crore fresh equity shares. The price band is Rs 86–91 per share. The IPO proceeds will fund expansion and debt repayment. Anand Rathi suggests subscribing for the long term. Listing is scheduled on NSE SME on September 3.
Gem Aromatics IPO allotment likely today; GMP at 9%. Here’s how to check status
Gem Aromatics IPO allotment will be finalized today, with shares set to debut on BSE and NSE on August 26. The IPO, subscribed 30.45 times, saw strong interest from QIBs and NIIs. Investors can check their allotment status via KFinTech or the NSE website.
Medistep Healthcare shares list at 23% premium over IPO price on NSE SME platform
Medistep Healthcare's shares began trading on the NSE SME platform. The shares opened at Rs 53, a 23% increase from the initial price of Rs 43. The IPO saw significant investor interest, subscribing 382.14 times overall. The company plans to use the funds for working capital and expansion. Medistep Healthcare reported revenue of Rs 49.66 crore for FY25.
Medistep Healthcare IPO opens today. Check GMP, issue size, price band and other details
Medistep Healthcare, an Ahmedabad-based pharmaceutical and wellness company, is launching its Rs 16.10 crore IPO on August 8 via the NSE SME platform. The IPO, priced at Rs 43 per share, has seen strong investor interest, with grey market premium surging to 40%.
SME IPO: Medistep Healthcare's Rs 16-cr public issue to open on Aug 8
Pharmaceutical firm Medistep Healthcare is set to raise a little over Rs 16 crore through its initial public offering (IPO), which opens for subscription on August 8.
Influx Healthtech shares list at 38% premium over IPO price on NSE SME
Influx Healthtech debuted strongly on the NSE SME platform, listing at Rs 132.5 per share, a 38% premium over its IPO price of Rs 96. The Rs 58.57 crore IPO, which closed on June 20, surpassed grey market expectations.
Influx Healthtech IPO subscribed over 41 times on Day 3; GMP signals strong listing
Influx Healthtech's IPO witnessed an overwhelming response, being oversubscribed 41.07 times, driven by strong retail and NII participation. The IPO, priced at Rs 91-96, saw grey market premiums suggesting a 39% listing gain. The company plans to use the raised funds to establish new manufacturing facilities for nutraceutical and veterinary products.
Influx Healthtech IPO subscribed 1.7 times on Day 1; GMP points to strong listing pop
Influx Healthtech IPO: In the unlisted market, Influx Healthtech’s grey market premium (GMP) was Rs 42 at 11:54 AM on Wednesday, suggesting a potential listing price of Rs 138 — a 43.75% premium over the issue’s upper price band of Rs 96 per share.
Influx Healthtech IPO opens today: Check key details before subscribing
Influx Healthtech, a Mumbai-based CDMO, launches its IPO today, aiming to raise ₹55.63 crore through a fresh issue and offer-for-sale. The IPO, priced between ₹91 and ₹96 per share, will close on June 20 and list on NSE SME on June 25. Proceeds will fund new manufacturing units and general corporate purposes.
Patanjali Foods' profit surges despite revenue dip, edible oil boosts bottomline
In a quarter when the promoters of Patanjali Foods - yoga guru Baba Ramdev and aide Acharya Balkrishna - had to issue an apex court-ordered public apology, the performance of the company didn't seem too adversely affected.
Pharma companies against plan to bring nutraceuticals under drug regulator
Controversy arises as government considers shifting nutraceuticals to drug regulatory authority from FSSAI oversight. Industry experts express reservations and call for detailed discussions. Nutraceutical segment set to reach $18 billion in India by 2025.
Nutraceuticals may get cheaper as panel looks to regulate prices
The Indian government is contemplating bringing nutraceuticals under price control to enhance affordability for consumers. Currently regulated by the Food Safety and Standards Authority of India (FSSAI) without price controls, these products, often marketed as over-the-counter health supplements, face scrutiny for high pricing. Officials argue that some companies charge exorbitant prices by repackaging pharmaceutical ingredients into nutraceuticals. A committee involving various health and regulatory bodies aims to introduce pricing regulations to curb this trend and ensure fair pricing.
Kronox Lab Sciences IPO opens for subscription. Should you bid?
Kronox Lab Sciences IPO, consisting solely of an offer for sale, presents potential for sustainable growth, with analysts recommending subscription. The issue, open until June 5, allocates 50% to QIBs, 15% to NIIs, and 35% to retail investors.
Govt panel to review if nutraceuticals should be brought under CDSCO
Nutraceuticals are products derived from food sources that are believed to provide extra health benefits besides the basic nutritional value found in foods.
SME IPO: Accent Microcell shares double on listing, investors make 125% return
The SME IPO was subscribed by a whopping 362 times on the last day of the bidding process with the total bids surpassing the Rs 18,000 crore mark, which is a first for any SME company. The previous record was held by Chennai-based Basilic Fly Studio, whose SME offer garnered bids of just over Rs 14,000 crore.
At Rs 18,800 cr, Accent Microcell gets highest bids in SME IPO history. Check GMP and allotment date
The SME IPO of Accent Microcell was subscribed by a whopping 362 times at close with the total bids surpassing the Rs 18,000 crore mark, which is a first for any SME company.
SME IPO: Accent Microcell issue to open on December 8. 10 things to know
The IPO opens on December 8 and will close on December 12. The final allotment will likely be made on December 13. The company's shares will likely get listed on December 15.
Historic debut! Sigachi Industries lists on stock exchanges at a premium of 252%
The initial stake sale of Sigachi Industries was open for subscription between November 1-3. It raised Rs 125.43 crore via the primary route, selling its shares in the range of Rs 161-163 a piece.
Sigachi Industries GMP: Will it pull a Paras Defence on listing?
Ahead of its listing on Monday, the scrip was trading at a premium of Rs 220 apiece, which is about 135 per cent over its issue price of Rs 163.
SME IPO Valencia Nutrition kicks off; issue receives bids for 84,000 shares
By 11.45 pm, the issue had received bids for 84,000 shares on BSE.
Open to changes in new standards for food supplements: FSSAI
FSSAI CEO Pawan Kumar Agarwal expressed concern over the increasing number of spurious food supplement products in the market.
Load More
